Evidence supporting the use of: Curcumin
For the health condition: Blood Clots (prevention of)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the active compound in turmeric, has been studied for its potential effects on blood clot prevention due to its anti-inflammatory and anticoagulant properties. Several in vitro (test tube) and animal studies suggest that curcumin can inhibit platelet aggregation and modulate various pathways involved in coagulation, such as reducing the expression of clotting factors and enhancing fibrinolysis (the breakdown of clots). Some mechanisms attributed to curcumin include inhibition of thromboxane, suppression of tissue factor expression, and modulation of endothelial function, all of which may contribute to reduced clot formation.

However, evidence in humans remains limited. A few small clinical trials and observational studies have indicated that curcumin supplementation can modestly reduce markers of coagulation or platelet activity in healthy volunteers or in individuals with cardiovascular risk factors. Despite these promising signs, there is a lack of large, high-quality randomized controlled trials directly demonstrating that curcumin supplementation reduces the risk of clinically significant blood clots (such as deep vein thrombosis or pulmonary embolism) in humans.

In summary, while preclinical research and early-phase human studies provide a scientific rationale for curcumin’s potential to support blood clot prevention, the current level of evidence is modest (rated 2/5). Curcumin should not be relied upon as a sole preventive or treatment strategy for blood clots, especially in high-risk individuals, until more robust clinical data are available.

More about curcumin
More about Blood Clots (prevention of)